Key terms
About PSTX
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PSTX news
Yesterday
4:55am ET
Poseida Therapeutics management to meet with Piper Sandler
Apr 22
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Apr 18
7:10am ET
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
Apr 18
3:55am ET
Poseida Therapeutics: A Strong Buy on Innovative Gene Therapy Advancements and Strategic Focus
Apr 17
9:32am ET
Poseida Therapeutics Shares Genetic Medicine R&D Insights
Apr 16
3:05pm ET
Poseida Therapeutics management to meet with Piper Sandler
Apr 08
5:25pm ET
Poseida Therapeutics (PSTX) Gets a Buy from William Blair
Apr 08
5:04pm ET
Poseida Therapeutics files to sell 8.33M shares of common stock for holders
Apr 08
4:42pm ET
Poseida Therapeutics Unveils Cancer Research Breakthroughs at AACR
Apr 08
12:06pm ET
Poseida: Phase 1 data supports potential of P-BCMA-ALLO1 therapy in MM
Mar 25
4:06pm ET
Poseida Therapeutics names Syed Rizvi, M.D., as Chief Medical Officer
Mar 13
4:07pm ET
Poseida Therapeutics granted FDA orphan designation for P-BCMA-ALLO1
Mar 12
6:58pm ET
Poseida Therapeutics’ treatment of multiple myeloma gets FDA orphan designation
Mar 11
2:32am ET
3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
Mar 08
7:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Mar 08
6:28am ET
Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates
Mar 08
5:25am ET
William Blair Sticks to Its Buy Rating for Poseida Therapeutics (PSTX)
Mar 07
4:26pm ET
Poseida Therapeutics Announces Executive Leadership Change
Mar 07
4:12pm ET
Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)
No recent press releases are available for PSTX
PSTX Financials
Key terms
Ad Feedback
PSTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PSTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
